Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLGF

PLGF

Brief Information

Name:Placental Growth Factor
Target Synonym:PGFL,Placental Growth Factor-Like,SHGC-10760,D12S1900,PlGF-2,PIGF,Placenta growth factor,PlGF,PGF,Placental Growth Factor,Placental Growth Factor, Vascular Endothelial Growth Factor-Related Protein
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

PGF-H5256-ELISA
 PLGF ELISA

Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PlGF-1 Protein, Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).

PGF-H5255-MALS-HPLC
PLGF MALS images

The purity of Human PLGF-3 Protein, Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.

Synonym Name

PGF,PLGF,PlGF,PGFL,SHGC-10760

Background

Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Approved Momenta, Mylan Nv EU Diabetes Complications; Myopia, Degenerative; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion Viatris Ltd 2023-09-15 Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Approved Qilu Pharmaceutical Co Ltd Mainland China Macular Degeneration; Diabetic macular oedema Qilu Pharmaceutical Co Ltd 2023-12-13 Diabetic macular oedema; Macular Degeneration Details
Aflibercept BAY-865321; BAT-86-5321 Approved Bayer AG Eylea, 艾力雅 United States Macular Degeneration; Macular Edema Regeneron Pharmaceuticals Inc 2011-11-18 Retinitis Pigmentosa; Choroidal Neovascularization; Carcinoma, Non-Small-Cell Lung; Corneal Neovascularization; Retinopathy of Prematurity; Neoplasm Metastasis; Diabetic Retinopathy; Retinal Vein Occlusion; Macular Degeneration; Vitreous Hemorrhage; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Diabetic macular oedema; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Colonic Neoplasms; Central Serous Chorioretinopathy; Neoplasms; Diabetes Mellitus, Type 2; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract Details
Ziv-aflibercept BAY-865321; AVE-0005 Approved Sanofi Zaltrap United States Colorectal Neoplasms Sanofi-Aventis U.S. Llc 2012-08-03 Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc Details
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Approved Momenta, Mylan Nv EU Diabetes Complications; Myopia, Degenerative; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion Viatris Ltd 2023-09-15 Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Approved Qilu Pharmaceutical Co Ltd Mainland China Macular Degeneration; Diabetic macular oedema Qilu Pharmaceutical Co Ltd 2023-12-13 Diabetic macular oedema; Macular Degeneration Details
Aflibercept BAY-865321; BAT-86-5321 Approved Bayer AG Eylea, 艾力雅 United States Macular Degeneration; Macular Edema Regeneron Pharmaceuticals Inc 2011-11-18 Retinitis Pigmentosa; Choroidal Neovascularization; Carcinoma, Non-Small-Cell Lung; Corneal Neovascularization; Retinopathy of Prematurity; Neoplasm Metastasis; Diabetic Retinopathy; Retinal Vein Occlusion; Macular Degeneration; Vitreous Hemorrhage; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Diabetic macular oedema; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Colonic Neoplasms; Central Serous Chorioretinopathy; Neoplasms; Diabetes Mellitus, Type 2; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract Details
Ziv-aflibercept BAY-865321; AVE-0005 Approved Sanofi Zaltrap United States Colorectal Neoplasms Sanofi-Aventis U.S. Llc 2012-08-03 Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aflibercept biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Macular Degeneration Details
Aflibercept biosimilar (Amgen) ABP-938 Phase 3 Clinical Amgen Inc Vascular Diseases; Macular Degeneration Details
Aflibercept Biosimilar(Alvotech Swiss) AVT-06 Phase 3 Clinical Alvotech Swiss Ag Vascular Diseases; Macular Degeneration Details
Aflibercept biosimilar (HEXAL/Sandoz) SOK-583A1; SOK583A1; SOK-583 Phase 3 Clinical Sandoz, Hexal Macular Degeneration Details
CT-P42 CT-P42 Phase 3 Clinical Celltrion Inc Macular Edema; Diabetic macular oedema Details
Aflibercept biosimilar (Mabwell) 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd Diabetic macular oedema Details
FYB-203 FYB-203 Phase 3 Clinical Macular Degeneration Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Wet Macular Degeneration; Macular Degeneration Details
Aflibercept biosimilar (Samsung Bioepis) SB-15; AM003; SB15 Phase 3 Clinical Samsung Bioepis Co Ltd Solid tumours; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) LY-09004; BA-9101; OT-702 Phase 3 Clinical Luye Pharma Group Ltd Wet Macular Degeneration; Macular Degeneration Details
Anti-placental growth factor monoclonal antibody αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 Phase 2 Clinical Thrombogenics, Bioinvent International Ab Retinal Telangiectasis; Ovarian Neoplasms; Solid tumours; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Diabetes Mellitus; Macular Degeneration; Carcinoma, Hepatocellular Details
4D-150 4D-150 Phase 2 Clinical 4d Molecular Therapeutics Inc Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012; BA-1103 Phase 1 Clinical Colorectal Neoplasms Details
PB-101 PB-101 Phase 1 Clinical Panolos Bioscience Inc Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular Details
Aflibercept biosimilar (Zein Bioteccnology) Phase 1 Clinical Zein Bioteccnology Co Ltd Diabetic macular oedema Details
Aflibercept biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Macular Degeneration Details
Aflibercept biosimilar (Amgen) ABP-938 Phase 3 Clinical Amgen Inc Vascular Diseases; Macular Degeneration Details
Aflibercept Biosimilar(Alvotech Swiss) AVT-06 Phase 3 Clinical Alvotech Swiss Ag Vascular Diseases; Macular Degeneration Details
Aflibercept biosimilar (HEXAL/Sandoz) SOK-583A1; SOK583A1; SOK-583 Phase 3 Clinical Sandoz, Hexal Macular Degeneration Details
CT-P42 CT-P42 Phase 3 Clinical Celltrion Inc Macular Edema; Diabetic macular oedema Details
Aflibercept biosimilar (Mabwell) 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd Diabetic macular oedema Details
FYB-203 FYB-203 Phase 3 Clinical Macular Degeneration Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Wet Macular Degeneration; Macular Degeneration Details
Aflibercept biosimilar (Samsung Bioepis) SB-15; AM003; SB15 Phase 3 Clinical Samsung Bioepis Co Ltd Solid tumours; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) LY-09004; BA-9101; OT-702 Phase 3 Clinical Luye Pharma Group Ltd Wet Macular Degeneration; Macular Degeneration Details
Anti-placental growth factor monoclonal antibody αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 Phase 2 Clinical Thrombogenics, Bioinvent International Ab Retinal Telangiectasis; Ovarian Neoplasms; Solid tumours; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Diabetes Mellitus; Macular Degeneration; Carcinoma, Hepatocellular Details
4D-150 4D-150 Phase 2 Clinical 4d Molecular Therapeutics Inc Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012; BA-1103 Phase 1 Clinical Colorectal Neoplasms Details
PB-101 PB-101 Phase 1 Clinical Panolos Bioscience Inc Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular Details
Aflibercept biosimilar (Zein Bioteccnology) Phase 1 Clinical Zein Bioteccnology Co Ltd Diabetic macular oedema Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message